Eric Bouteiller

Eric Bouteiller
Eric is a seasoned business leader and an international advisor in cross-border partnerships and projects in healthcare in China. He co-founded Jumo Partners where he is focusing on three areas: Strategic Direction, Alliance Management and Public Affairs. Value creation for customers and shareholders is a permanent professional objective. He is also the Lead for Life Science and Health Sector at Cornerstone in China and Adjunct Professor of Management at CEIBS. Eric worked for Ipsen in China for 16 years, making it the second largest affiliate of the Group. He joined Ipsen Group as General Manager of Ipsen China (2001–2011). He …
Eric is a seasoned business leader and an international advisor in cross-border partnerships and projects in healthcare in China. He co-founded Jumo Partners where he is focusing on three areas: Strategic Direction, Alliance Management and Public Affairs. Value creation for customers and shareholders is a permanent professional objective. He is also the Lead for Life Science and Health Sector at Cornerstone in China and Adjunct Professor of Management at CEIBS.

Eric worked for Ipsen in China for 16 years, making it the second largest affiliate of the Group. He joined Ipsen Group as General Manager of Ipsen China (2001–2011). He was then promoted to Senior Vice President for Asia Operations supervising Asian markets for Consumer Healthcare (2012-2017). He was involved in several prominent business organizations in China. He was one of the founders of Tianjin Chapter of the European Union Chamber of Commerce in China (EUCCC) that he chaired from 2008 to 2011. He co-founded the “French HealthCare Alliance for China” (2013-2014), which brings together all French companies investing in China. He was Vice Chairman (2011-2015) then Chairman (2016-2017) of the Research & Development based Pharmaceutical Association in China (RDPAC). Eric has been a French Trade Advisor since 2007.

In 1990, he joined HEC Eurasia Institute, a think tank of the HEC School of Management, where he took part in setting up Asian and Chinese strategies for several French and European companies.

Eric holds a PhD in Organizational Sociology and is a certified independent Director (UK Institute of Directors).
See more

Articles: Eric Bouteiller

China Strives for First-In-Class Drug Innovation with New Patent Law

China / In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of China’s revision to its patent law on the country’s domestic biopharma innovation landscape and the ability of breakthrough drugs from MNCs to make it onto the Chinese market.    July 2021 was a…

China’s National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?

China / Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why a more streamlined and data driven review process is positive news for the innovative pharmaceutical industry. However, Bouteiller cautions that the race to the bottom…

Opinion: The Chinese Doctor-Patient Relationship in the Digital Era

China / I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in China (Club Santé Chine). I would like to share here some learnings and personal thoughts.   One of the consequences of the COVID-19 crisis has…

Key Challenges for Life Sciences & Healthcare in 2020: Leadership

Global / ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on leadership. Click here to read the full report.   The first impression listening to CEOs and leaders was their…

Key Challenges for Life Sciences & Healthcare in 2020: Strategy

Global / ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on strategy. Click here to read the full report.   Compared to other businesses, strategy in LSH is characterized…

A New Paradigm for Rare Diseases in China

China / Eric Bouteiller outlines the paradigm shift occurring in China around rare diseases and how the country has the potential to lead the global pharmaceutical industry in this vital area.   Through exchanges with public officials, academics, representatives of patient associations and industry experts, we sensed a paradigm shift The 8th China Rare Disease Summit held…

Chengdu: The First Steps Towards Mutual Insurance In China

China / Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps into China and the potential impact of mutual insurance – whereby the insurance company is owned entirely by its policyholders – on the world’s second…

The Ideal Pharma Country Manager: China (Cornerstone International)

China / What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of  Cornerstone International Group outline what they look for in potential candidates for country manager positions in China.   The Ideal China Country Manager Needs to Have:…

See more